Dividend Policy and AFFO/FFO Metrics
Coherus has never paid a dividend and does not plan to pay any in the foreseeable future (news.futunn.com). Management explicitly states that it intends to reinvest cash into the business (especially R&D and product launches) rather than return capital to shareholders (news.futunn.com) (news.futunn.com). As a clinical-stage biotech with ongoing losses, this approach is expected – any shareholder returns will come via stock price appreciation if the company’s strategy succeeds (news.futunn.com). Dividend yield is 0%, and there is no history of payouts. Additionally, AFFO/FFO metrics are not applicable here, as those are REIT cash flow measures; Coherus’s performance is better gauged by its net income (LOSS) and cash burn rather than funds from operations.
Q4 2025 Earnings Performance – What to Expect
LOQTORZI sales growth is the central metric to watch. In Q3 2025, LOQTORZI (toripalimab) net revenue was $11.2 million, up 12% sequentially from $10.0M in Q2 (rss.globenewswire.com). Year-over-year growth was striking (92% vs. $5.8M in Q3 2024) (rss.globenewswire.com), reflecting the ramp-up after its late-2023 FDA approval. However, the revenue base remains modest – likely around the low teens of millions per quarter – given LOQTORZI is currently approved only for nasopharyngeal carcinoma (a niche indication). The upcoming Q4 report will reveal if uptake is accelerating (e.g. via broader oncologist adoption after favorable NCCN guideline inclusion) (investors.coherus.com) or leveling off.
Profitability: Investors anticipate another net loss for Q4, though reduced from year-ago levels. Through the first nine months of 2025, Coherus’s continuing operations had a net loss of $136.8 million (–$1.18 per share), which was an improvement from the $169.3M loss in the same period of 2024 (rss.globenewswire.com). Aggressive cost-cutting post-divestitures (including lower headcount and operating expenses) has narrowed losses (rss.globenewswire.com). For example, Q3 2025’s net loss from continuing ops was $44.5M (–$0.38 per share) vs. $47.6M (–$0.41) in Q3 2024 (rss.globenewswire.com). In Q4 2025, analysts will look for continued expense discipline – R&D spending may actually tick up as pipeline programs progress, but SG&A should reflect the slimmer commercial portfolio. Any one-time items will also be scrutinized; note that in Q2 2025 Coherus booked a $10.3M loss on debt extinguishment (tied to refinancing) and a huge $339M gain from the Udenyca sale in discontinued ops (investors.coherus.com), but such outsized items are not expected in Q4. Overall, expect an EPS loss (consensus for Q3 was –$0.29, which Coherus slightly missed at –$0.30 (financhill.com); a similar range of loss likely continued in Q4). The Q4 call will be key for any 2026 guidance on LOQTORZI sales or cash runway updates, as management has previously projected having cash through 2026 (i.e. no need for immediate financing) (investors.coherus.com).
Balance Sheet, Leverage & Debt Maturities
Coherus’s balance sheet was dramatically strengthened by the asset sales. As of Q3 2025, cash, equivalents and marketable securities totaled $191.7 million (rss.globenewswire.com) (up from $126M at 2024 year-end). This figure was higher earlier in 2025 ( ~$238M at Q2’25) after the Udenyca sale proceeds came in (investors.coherus.com) (investors.coherus.com), but the company has been utilizing cash to fund operations and pay certain obligations. Notably, Coherus retained about $67.0M of UDENYCA-related rebates and fees that Intas did not assume; these are being paid off in a “front-loaded” fashion through late 2025 and into 2026 (investors.coherus.com). This likely absorbed a chunk of cash in Q4. Even so, Coherus is expected to finish 2025 with well over $150M in cash on hand – a substantial cash runway that, by management’s estimate, is sufficient through 2026 to reach key drug data readouts (investors.coherus.com).
Leverage: Coherus used its 2024–25 windfall to dramatically deleverage. During Q2 2025, the company paid down “substantially all” of its $230 million in outstanding 2026 convertible notes (investors.coherus.com). Approximately $170M of the converts were repurchased in April 2025 and the remaining ~$60M were settled after the Udenyca sale closed (www.biospace.com) – effectively eliminating this debt overhang. At the same time, Coherus bought out the royalty rights on UDENYCA’s net sales that it had previously sold as part of a financing arrangement (investors.coherus.com). With those actions, Coherus exited 2025 largely debt-free, save for a single term loan: a $38.7 million senior secured term loan facility maturing 2029 (rss.globenewswire.com). This 2029 term loan (entered in May 2024) carries interest expense of a few million per year – in Q3 2025, interest expense was $2.3M, which included interest on that loan and on the remaining LOQTORZI revenue participation obligation (rss.globenewswire.com). Importantly, Coherus’s interest coverage is not a near-term concern, as the company actually earned almost $2.1M in interest income in Q3 from its large cash balance (rss.globenewswire.com) – nearly offsetting the interest expense. With no major maturities until 2029, Coherus has breathing room on debt. The key solvency watch-point is not scheduled debt repayments but rather the cash burn rate, since continued operating losses could eventually force new financing by late 2026 if no positive inflection occurs.
Valuation Considerations
Coherus’s stock has languished amid its transition. Shares trade around $1.50–$2.00, which implies a market capitalization near $200 million (at ~$1.61/share, market cap was $194.6M) (www.alphaspread.com). Notably, this market cap is roughly on par with Coherus’s cash on hand, meaning the enterprise value (EV) – after subtracting ~$150–190M cash and adding $38.7M debt – is very low (on the order of ~$50–80M). In other words, the market is valuing the entire LOQTORZI franchise and immuno-oncology pipeline at only tens of millions of dollars. This depressed valuation reflects investor skepticism: Coherus is currently loss-making, and its top-line shrank dramatically after selling off revenue-generating assets. Traditional multiples like P/E are not meaningful due to negative earnings, and even price/sales is quite low – if LOQTORZI does about ~$40–45M in 2025 revenue, the stock trades at ~4–5× trailing sales (and EV/Sales far lower given net cash). By comparison, profitable biotech or pharma peers often trade at higher multiples, but Coherus’s single-product risk and cash burn weigh on its valuation. It’s worth noting that book value per share is around $0.75 (shareholders’ equity was $87.8M as of Q3) (rss.globenewswire.com), so the stock is priced at roughly 2× book – not unusual for a development-stage biotech. The upcoming earnings may prompt re-rating if management can demonstrate improving trends (e.g. accelerating sales or reduced cash burn), but for now the stock’s low valuation signals caution. As UBS concluded in an August 2024 downgrade, Coherus’s asset sales, while boosting liquidity, lowered its future revenue trajectory – UBS projected a –4% revenue CAGR from 2024 to 2028 (versus +13% previously) and cut its price target to $1.50 (za.investing.com). This underscores the market’s current view that growth will be an uphill battle absent new revenue streams.
Key Risks and Red Flags
Coherus faces significant execution and financial risks as it pivots to oncology:
- Sustainability of LOQTORZI Sales: LOQTORZI is now Coherus’s sole marketed product. Its success in nasopharyngeal carcinoma is encouraging, but that is a limited market. Competition in the PD-1 inhibitor space is intense (dominated by Merck’s Keytruda, etc.), and although LOQTORZI has the niche NPC approval, any expansion to broader cancers will pit it against entrenched rivals. The upcoming data for LOQTORZI in combination trials (e.g. in non-small cell lung cancer) must be compelling to drive wider use. If LOQTORZI uptake stalls or if adverse safety signals emerge, Coherus would have no other revenue source (za.investing.com).
- Ongoing Cash Burn: Even after divestitures, Coherus continues to operate at a substantial net loss (9M 2025 continuing ops lost $136.8M) (rss.globenewswire.com). The company is not expected to break even in the short term, so it will keep consuming cash to fund R&D and commercialization. At the Q2 2025 update, management insisted it has a “cash runway through 2026” (investors.coherus.com), but this assumes no major setbacks. If expenses stay elevated or LOQTORZI underperforms, Coherus may need to seek additional capital by 2026, which could mean dilutive equity offerings or new debt. Any hint of accelerated cash burn in the Q4 results (e.g. a big working capital outflow or higher R&D spend) would be a red flag.
- Pipeline and R&D Uncertainty: Coherus’s future hinges on its early-stage immunotherapy pipeline – notably CHS-114 (CCR8-targeted antibody) and casdozokitug (IL-27 antagonist) – which are in Phase 1/2 trials (www.biospace.com). These are high-risk, unproven assets. Positive clinical data could unlock huge upside (and partnering opportunities), but results won’t read out until 2026 (investors.coherus.com). There is significant clinical risk here: if these trials disappoint, Coherus will have spent precious cash with little to show, and its pipeline valuation could evaporate. The market’s current low EV suggests skepticism on pipeline success.
- Loss of Diversified Revenue: The company’s strategic asset sales mean it no longer benefits from the steady revenue of its prior biosimilars (which, while lower-margin and facing competition, did generate over $250M annually (www.biospace.com)). Coherus is essentially “betting the farm” on oncology. This all-eggs-in-one-basket strategy heightens risk – any stumble in LOQTORZI or the pipeline could leave the company with minimal revenue. UBS analysts noted the post-divestiture revenue outlook is actually one of decline, not growth (za.investing.com). Investors are cautious that Coherus traded short-term liquidity for long-term revenue contraction.
- Regulatory and Partner Risks: LOQTORZI is licensed from Shanghai Junshi Biosciences, which means Coherus relies on a partner for the drug’s supply and further development in some geographies. Geopolitical or regulatory complications (e.g. U.S.-China tensions affecting the supply chain or data sharing) could pose risks. Additionally, Coherus’s ability to license its pipeline abroad (as it did in Canada for toripalimab (news.futunn.com)) or bring in partners will influence its success. Failure to secure partnerships for ex-U.S. markets or for co-development could limit the drugs’ potential and strain Coherus’s resources since it cannot commercialize globally alone.
Open Questions Ahead of the Earnings Call
As Coherus prepares to report Q4 2025 results on March 9, 2026, several critical questions face management and investors:
- Will LOQTORZI’s growth justify the asset sales? The company sacrificed revenue-rich franchises to focus on LOQTORZI. Q4 results will show if LOQTORZI sales are ramping fast enough to signal eventual profitability, or if uptake is too slow to close the gap.
- How long will Coherus’s cash last, truly? Management claims a cash runway through 2026 (investors.coherus.com), but investors will parse the Q4 cash flow and year-end cash balance to judge if additional funding might be needed sooner. An update on whether cash burn is trending down (or any plans to cut costs further) will be key.
- Will there be any guidance or deals announced? Given the uncertainty, Coherus might provide 2026 guidance for LOQTORZI sales or operating expenses to instill confidence. Likewise, any hints of partnership deals (e.g. ex-U.S. licensing of toripalimab in Europe or other pipeline collaborations) would be eagerly welcomed. Absent such news, the market may remain wary.
- Are pipeline milestones on track in 2026? Investors will look for management’s commentary on the timelines for CHS-114 and casdozokitug trial readouts. These data in 1H 2026 are potential inflection points (investors.coherus.com). Any delays or safety concerns would be a negative surprise, whereas confirming they remain “on track” (as previously stated) (investors.coherus.com) will sustain hope.
- What’s the plan if things go off course? Perhaps the biggest question: Plan B. If LOQTORZI fails to grow substantially or if the pipeline disappoints, how will Coherus respond? The company has no more big assets to sell. Clarity on contingency plans – be it further cost cuts, refocusing on a niche, or exploring strategic alternatives – would reassure investors that management is prudently preparing for all outcomes.
Sources: Coherus investor press releases and filings (rss.globenewswire.com) (investors.coherus.com) (news.futunn.com); earnings call highlights and media reports (rss.globenewswire.com) (za.investing.com). These provide the factual basis for the financial figures, strategic actions, and risk factors discussed above. Coherus’s Q4 2025 report will be closely analyzed against this backdrop as the company enters 2026 at a pivotal juncture.
